ContributorsPublishersAdvertisers

Part 2: Venetoclax and PI3K Inhibition for Relapsed/Refractory CLL

targetedonc.com
 2021-11-22

Cover picture for the articleDuring a live virtual event, Danielle Brander, MD, discussed with participating physicians second-line treatment options for patients with chronic lymphocytic leukemia, with questions guided by Targeted Oncology. Targeted Oncology™: How is venetoclax (Venclexta) used in CLL?. BRANDER: Venetoclax/rituximab [Rituxan] in the relapsed/refractory setting was compared 1:1 with BR [bendamustine/rituximab]...

www.targetedonc.com

Comments / 0

Comments / 0